EQS-News

Invictus Pharmacy First to Accept Crypto for Prescriptions 13.11.2025, 14:35 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Invictus Pharmacy / Key word(s): Product Launch
Invictus Pharmacy First to Accept Crypto for Prescriptions

13.11.2025 / 14:35 CET/CEST
The issuer is solely responsible for the content of this announcement.


Disrupting pharmacy payments with ETH, SOL, and XRP acceptance nationwide; online rollout set for Jan. 1, 2026.

NEW YORK, Nov. 13, 2025 /PRNewswire/ -- Invictus Pharmacy, a pharmacist-founded and nationally licensed pharmacy network, announced today that it will begin accepting cryptocurrency as a form of payment from patients. This milestone makes Invictus Pharmacy the first nationwide licensed pharmacy to embrace digital assets as part of its patient payment infrastructure.

Invictus Pharmacy

Beginning immediately, cryptocurrency payments including Ethereum (ETH), Solana (SOL), and XRP (Ripple) will be accepted at all Invictus Pharmacy retail locations. Starting January 1, 2026, patients will also be able to utilize these digital payment options through the company's online platform at InvictusPharmacy.com.

Key Benefits of Invictus Pharmacy's acceptance of cryptocurrency include:

  • Enhanced Security: Blockchain technology provides a secure and transparent platform for all transactions, reducing the risk of fraud.
  • Faster Transactions: Cryptocurrency transactions are typically faster than traditional payment methods, allowing for quicker processing of prescriptions.
  • Increased Accessibility: Accepting cryptocurrency opens up access to pharmaceutical services for younger demographics who prefer or are comfortable using digital currencies.
  • Transparency: Every transaction is recorded on the blockchain, creating a transparent and auditable trail.

Pioneering Transparency in the Pharmaceutical Payment System

This initiative represents the first phase of a larger technological movement led by Invictus Ventures Inc., the management company of Invictus Pharmacy. Invictus Ventures is developing a blockchain-based payment infrastructure designed specifically for the U.S. prescription drug market. The platform will facilitate instant, transparent, and auditable transactions between payers, manufacturers, pharmacies, and patients.

By accepting cryptocurrency payments, Invictus Pharmacy is also embracing the next generation of American consumers who are more comfortable and familiar with digital assets and alternative payment methods. This forward-looking approach reflects Invictus's commitment to modernizing the pharmacy experience, meeting patients where they are, and fostering financial accessibility through innovation.

By leveraging the power of blockchain technology, Invictus aims to eliminate the administrative lag and opacity that define today's pharmacy benefit model, replacing it with a real-time, programmable payment system that benefits every stakeholder in the chain.

"Pharmacy Benefit Managers (PBMs) were invented before the era of the internet to combat rising drug prices in the 1970s," said Meyer Davidoff, Founder and CEO of Invictus Pharmacy. "While their original purpose was to negotiate fair pricing and streamline reimbursements, PBMs have since evolved into powerful intermediaries that obscure true drug costs, delay payments to pharmacies, and inflate prices for patients. The system has become a labyrinth of rebates, clawbacks, and opaque contracts that benefit middlemen rather than patients or providers.

Today, PBMs act as central toll collectors in a system that should be moving toward openness and modern technology. Accepting cryptocurrency is more than offering another way to pay. It is the first step toward building a faster and more transparent payment network that links patients, pharmacies, and manufacturers with far fewer barriers. This is the future of pharmacy, a system where information and payments move quickly, clearly, and efficiently for everyone."

"For our patients, using cryptocurrency will feel just as simple as paying with a smartphone or credit card," said Alan Oustaev, Chief Operating Officer of Invictus Pharmacy. "Our goal is to make the experience seamless both in-store and online, giving patients more choice and convenience while we modernize how prescription payments are made."

An Open Call to Industry Partners

Invictus Pharmacy Founder and CEO Meyer Davidoff is encouraging trading partners throughout the pharmaceutical supply chain, including drug manufacturers, wholesalers, and payers, to begin adding cryptocurrency to their balance sheets and to explore digital asset integration within their financial infrastructure.

"This is the first step of our grand vision to revolutionize the archaic payment system within our industry," said Davidoff. "We are actively building an additional blockchain-based payment rail upon which all stakeholders, from manufacturers to patients, will transact seamlessly and transparently."

This forthcoming network, being developed under Invictus Ventures, will serve as a digital settlement layer for prescription transactions, enabling instant fund transfers, automated rebate validation, and frictionless reimbursement flows. Once fully deployed, the system is expected to reduce claim processing times from weeks to seconds, setting a new benchmark for efficiency in U.S. healthcare payments.

About Invictus Pharmacy

Invictus Pharmacy, managed by New York–based Invictus Ventures Inc., is a vertically integrated, nationwide pharmacy platform founded in 2017. With a network of retail locations, a licensed mail-order pharmacy, a proprietary e-commerce platform, and claims adjudication technology, Invictus has served more than one million patients. Invictus was among the first pharmacy organizations to adopt a Direct-to-Consumer (DTC) model for its manufacturing partners, enabling brands to reach patients directly while bypassing traditional intermediaries. By partnering directly with manufacturers to offer direct-to-consumer pricing and adding cryptocurrency payment options with blockchain-enabled claims transparency, Invictus lowers costs, expands access, and advances a next-generation pharmacy model.

Website: www.invictuspharmacy.com

Invictus Ventures Management Logo

Logo - https://mma.prnewswire.com/media/2781498/Invictus_Pharmacy_Logo.jpg
Logo - https://mma.prnewswire.com/media/2821966/Invictus_Ventures_Management_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/invictus-pharmacy-first-to-accept-crypto-for-prescriptions-302614105.html

rt.gif?NewsItemId=EN23478&Transmission_Id=202511130830PR_NEWS_EURO_ND__EN23478&DateId=20251113


13.11.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2229492  13.11.2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 22:44 Uhr • Artikel • dpa-AFX

Gestern 22:14 Uhr • Artikel • dpa-AFX

Gestern 21:46 Uhr • Artikel • dpa

Gestern 21:40 Uhr • Artikel • dpa-AFX

Gestern 20:54 Uhr • Artikel • dpa-AFX

Gestern 20:47 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer